P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
Julia Rotow(University of California, San Francisco), C. Blakely(University of California, San Francisco), Anatoly Urisman(City College of San Francisco), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Robert C. Doebele(Aurora University), Dara L. Aisner(University of Colorado System), Johannes R. Kratz(University of California, San Francisco), Kirk D. Jones, Jonathan W. Riess(University of California Davis Medical Center), David M. Jablons(City College of San Francisco), Alexander R. Gupta(University of California, San Francisco), Thierry Jahan(University of California, San Francisco), Trever G. Bivona(University of California, San Francisco)
Cited by 8
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k